Table 1 Patients’ baseline characteristics.
Percentage | |
|---|---|
Nullipara | |
Yes | 50.5% (46/91) |
No | 49.5% (45/91) |
Histopathology | |
CHSIL | 60.4% (55/91) |
VaHSIL | 27.5% (25/91) |
CHSIL with vaHSIL | 8.8% (8/91) |
CHSIL with vHSIL | 1.1% (1/91) |
VaHSIL with vHSIL | 2.2% (2/91) |
HPV testing before treatment | |
Positive | 100.0% (91/91) |
Negative | 0.0% (0/0) |
HPV substyle before treatment | |
Single HPV16/18 | 45.0% (41/91) |
Other HR-HPV | 38.5% (35/91) |
HPV16/18 combined with other HR-HPV | 16.5% (15/91) |
HPV vaccination status before treatment | |
Yes | 6.6% (6/91) |
No | 93.4% (85/91) |
